Aug 13, 2026 4:15pm EDT Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 06, 2026 8:00am EDT Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Jul 14, 2026 8:00am EDT Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
Jun 26, 2026 8:00am EDT Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
May 12, 2026 8:00am EDT Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
May 08, 2026 8:00am EDT Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
Apr 16, 2026 8:00am EDT Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
Apr 07, 2026 8:00am EDT Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
Mar 30, 2026 4:50pm EDT Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results